Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer Cover

Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer

Radiology and Oncology

Volume 56 (2022): Issue 2 (June 2022)

By:

Jiwon Choi, Jiyoung Park, Ilyoung Cho and Yhunyhong Sheen

Open Access

|Apr 2022

Download Article

Download the full article as a PDF file.

DOI: https://doi.org/10.2478/raon-2022-0012 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099

Journal RSS Feed

Language: English

Page range: 185 - 197

Submitted on: Sep 26, 2021

Accepted on: Jan 28, 2022

Published on: Apr 7, 2022

Published by: Association of Radiology and Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 4 times per year

Keywords:

transforming growth factor-β (TGF-β),

epithelial-to-mesenchymal transition,

cancer stem cell,

Related subjects:

Clinical medicine,

Internal medicine,

Haematology, oncology,

© 2022 Jiwon Choi, Jiyoung Park, Ilyoung Cho, Yhunyhong Sheen, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 56 (2022): Issue 2 (June 2022)Next article